Epac (exchange protein activated by 3’-5’-cyclic adenosine monophosphate [cAMP]) has been investigated functionally and pathophysiologically as a potential therapeutic target of various diseases since it was identified in the late 90s as a novel cAMP target protein by two independent groups (1, 2). Two variants of Epac (Epac1 and Epac2) act as cAMP guanine-nucleotide exchange factors (GEFs) to activate the small GTPases Rap, Rap1, and Rap2 in a protein kinase A (PKA)-independent manner (1, 2), and Epac-activated Rap controls a variety of biological processes (3). The Epac1 and Epac2 proteins are encoded by two different genes:
In the brain, Epac2 expression in neurons is more abundant than but works with Epac1 to regulate neural function (2). To elucidate the roles of Epac1 and Epac2 in the central nervous system, specific inhibitors and activators have been utilized, such as ESI-05, a selective inhibitor of Epac2 (7), Sp-8-BnT-cAMPS (S0220), a selective Epac2 activator (8), and 8-pCPT-2’-
The use of a variety of research tools has revealed the involvement of Epac in a diversity of neuronal functions, including neurotransmitter release (13), neurite growth, and neuronal/glial differentiation (14, 15), and in higher cognitive functions, such as memory, learning, and social interaction (12). This mini-review summarizes recent findings from research on Epac1 and Epac2, and provides an overview of their diverse roles in the central nervous system. Findings in this emerging field may have implications both for the clinics and for society, and may provide new insights into novel therapeutic approaches for neurological and psychiatric disorders.
It is well known that synaptic remodeling of spine structures (16) and synaptic plasticity (17) are the two key synaptic mechanisms that underlie the anatomical and physiological bases, respectively, of learning and memory formation. Among the variety of molecular events that mediate these processes, cAMP represents a key intracellular signal that regulates the morphological plasticity of dendritic spines (18) and long-term potentiation (LTP) of synapses (19-21) through cAMP response element binding protein (CREB) or PKA. However, Epac is also involved in synaptic morphology and plasticity.
In cultured mature rat cortical neurons, which express smaller amounts of Epac1 than Epac2, 8-CPT-induced activation of Epac2 results in spine shrinkage, decreased spine motility, and depressed excitatory transmission, with removal of GluA2/3-containing AMPA receptors from synapses. These Epac2-mediated effects were confirmed
Further electrophysiological studies using Epac2 KO mice or ESI-05 have shown that Epac2 is involved in cAMP-dependent potentiation of hippocampal mossy fiber synapses (13) and LTP at parallel fiber-to-Purkinje cell synapses via activation of GluA3-containing AMPA receptors (24). Yang
Although specific effect of Epac1 or Epac2 was not demonstrated in the following studies, electrophysiological studies using 8-CPT revealed that the Epac-dependent increase of glutamate release at hippocampal excitatory synapses (25) is mediated by phospholipase C (26). Moreover, Epac activation contributes to the maintenance of LTP (27) and pituitary adenylate cyclase-activating polypeptide (PACAP)-induced LTD (28) via extracel-lular signal-regulated protein kinase (ERK) and p38 mitogen-activated protein kinase (MAPK), respectively, in the hippocampus (Fig. 2A). Therefore, effects of Epac on synaptic remodeling and plasticity may be different according to isoforms and these issues remain unresolved yet.
Neurite and axonal growth: Epac1 and Epac2 are differentially regulated during nervous tissue development. Whereas Epac1 is abundantly expressed in the brain at embryonic and neonatal periods but is almost undetectable in adulthood, Epac2 is lowly expressed at embryonic and neonatal stages and increased in the adult brain (29). These findings suggest that Epac1 has a more influential role than Epac2 in neurite outgrowth during development. In support of this, knockdown of Epac1 expression with short hairpin RNA (shRNA) in cultured hippocampal neurons results in fewer polarized neurons with shorter axons via Rap1B inhibition, and cultured hippocampal neurons from Epac1 KO mice display delayed polarization (9). In pheochromocytoma (PC-12) cells, Epac1 is involved in panaxydol-induced axonal growth via the Rap1-ERK-CREB pathway (30). However, through a Rap-independent mechanism, cAMP-mediated Epac1-dependent Rit activation induced by PACAP38 results in CREB-dependent neurite outgrowth in PC-6 cells (a subline of PC-12 cells) (31). Interestingly, cAMP- and Rap1-independent functions of Epac1 have a reverse effect on neurite outgrowth. For example, in the Neuro2a neuroblastoma cell line, Epac1 accumulates at the plasma membrane because of the lack of importin β1 and neither binds to cAMP nor activates Rap1, thereby inhibiting neurite outgrowth (Fig. 2B) (32).
We cannot rule out the possible involvement of Epac2 in neurite and axonal outgrowth, as both Epac1 and Epac2 are expressed throughout the brain. Indeed, RNA interference-mediated knockdown of Epac2 disrupts the architecture of basal dendrites via inhibition of Ras signaling in mature cortical neurons (33). Furthermore, activation of Epac2 with the specific agonist S-220 enhances the outgrowth of neurites from postnatal rat cortical neurons
Neurogenesis and glial differentiation: Although little is known about the role of Epac in neural differentiation during embryonic neurogenesis, Epac2 may be involved in adult neurogenesis in the ventricular-subventricular zone (V-SVZ) and subgranular zone (SGZ) of dentate gyrus, where it is expressed in GFAP-positive neural stem cells and doublecortin-positive neuroblasts and progenitor cells (39). A study using adult Epac2 KO mice showed that this protein is required for progenitor cell proliferation and neurogenesis in the SGZ (40). Other studies reported a role of Epac in the differentiation of glial cells, including astrocytes and oligodendrocytes. PACAP-induced astrocytic differentiation of neural precursor cells is mediated by Epac2A activation via calcium ion influx, leading to increased intracellular concentrations (14). Moreover, inhibition of Epac2 with ESI-05 revealed that Epac2 promotes cAMP-dependent differentiation of cultured rat oligodendrocyte precursor cells by regulating the expression of myelin basic protein (41). In addition, whereas cAMP-dependent proliferation of Schwann cells requires PKA activity, activation of Epac by 8-CPT is antiproliferative and also impacts the cAMP-dependent differentiation and myelin formation in peripheral Schwann cells (42). Thus, although little is known about an exact role of Epac1 in neurogenesis and glial differentiation, Epac, especially Epac2 isoform, appears critical for normal development of neurons and astrocytes, and might provide a new therapeutic target to enhance remyelination in the central and peripheral nervous systems.
Cell death is critical for homeostasis in organisms by eliminating excess and injured cells. Apoptosis and autophagy have been characterized as major types of programmed cell death (43). Although the roles of Epac have been extensively studied in cancer (44), less is known about the role of Epac on cell death in the central nervous system.
Apoptosis: Whereas cAMP-PKA signaling is neuroprotective, activation of Epac, such as by 8-CPT or adeno-associated virus-mediated overexpression of Epac1 or Epac2, induces apoptosis of cultured mouse cortical neurons by p38 MAPK-induced upregulation of Bim (known as a Bcl-2 interacting member and Bcl-2-like protein 11) (Fig. 2A) (45). Moreover, cortical neurons of Epac1 KO mice are protected from 3-propionic acid-induced apoptosis, and neurons cultured from Epac1 KO mice show decreased expression of Bim mRNA and protein (45). Furthermore, by using ESI-05 and a rat model of traumatic brain injury, inhibition of Epac2 was found to reduce the associated neuronal apoptosis (46, 47). Although these findings suggest that Epac1 and Epac2 have a proapoptotic effect in neurons, Epac exhibits antiapoptotic effects in other cells, such as hematopoietic B-CLL cells (48), macrophages (49), and cardiomyocytes (50). Thus, the pro- or antiapoptotic roles of Epac may vary according to cell type and may reflect the differential localization of Epac protein via membrane targeting activities of dishevelled, Egl-10, the pleckstrin domain (51), and Ras association domain (52).
mTOR-independent autophagy: Autophagy is an intracellular lysosomal process for the degradation of endogenous or exogenous materials in the cytoplasm (53). Two signaling pathways are involved in this process: mammalian target of rapamycin (mTOR)-dependent and mTOR-independent pathways (54). Contrary to the role of PKA in mTOR-independent autophagy (55), cAMP-Epac signaling may inhibit this autophagy by activating a series of components of Rap2B-PLC-ε-IP3 and Ca2+calpain-Gsα pathways (Fig. 2A) (56). In PC-12 cells, 8-CPT delays the clearance of autophagy substrates, and autophagy is induced by inhibiting Epac-activated Rap2B, indicating that Rap2B acts as a downstream regulator of Epac in the mTOR-independent autophagy pathway (56).
Several
In a postmortem study comparing protein levels of Epac1 and Epac2 in brain tissues from control and suicide groups, Epac2 was significantly higher in the prefrontal cortices and hippocampus of suicide victims with major depression disorder, whereas Epac1 protein expression did not differ from that in the controls (59). Contrary to data from human study, in the hippocampi of mice exposed to acute restraint stress which is used to model depression and anxiety disorders (60), the expression of Epac1 and Epac2 mRNAs was higher in female wild-type mice, and Epac KO mice showed delayed nuclear localization of glucocorticoid receptors along with altered serum corticosterone levels (60). In a study conducted by Zhou and colleagues, Epac2 KO mice displayed anxious and depressive behaviors in normal environments: they spent less time in the center of an open field and exhibited increased immobility during forced swimming test (40). However, other studies found no evidence that Epac2 deletion alters anxiety (10, 12). Although further study is needed to clarify these discrepancies, the current evidence suggests that Epac1 and Epac2 differentially affect emotional behaviors by regulating cellular responses to stress.
Screens for genes on human chromosome 2q revealed nonsynonymous variants in
Since the Epac protein was identified in 1998, accumulating data from scientific studies have clarified PKA-independent cAMP functions via Epac in various cell types and tissues. Moreover, specific activators/inhibitors of Epac isoforms and genetic manipulations have helped uncover the specific roles of Epac1 and Epac2 in a variety of tissues. This mini-review summarizes the specific roles of Epac1 and Epac2 in neural cells and tissues (Fig. 2B and 2C). Despite growing evidence suggesting that Epac is an essential protein in the cAMP signaling pathway in neural tissues, a lot of issues remain unsolved. For instance, Epac isoform-specific or Epac localization-dependent anatomical and physiological functions in neurons and higher cognitive functions during different life stages, from embryo to old age, similarly remain shrouded in mystery. Further isoform-specific gene manipulations or drug development specific for Epac2 isoforms will be helpful to elucidate their specific functions. In addition, the roles of Epac1 and/or Epac2 in molecular, physiological, and behavioral phenotypes determined in KO mice need further study. This is also critical for discovering the precise role of Epac proteins in the molecular and pathophysiological mechanisms underlying various diseases, including neurodegenerative and mental disorders.
K.L. was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education [NRF-2019R1F1A1063932].
The author has no conflicting interests.
Summary of Epac2 isoforms
Protein name | Epac2A1 | Epac2A2 | Epac2B | Epac2C |
---|---|---|---|---|
Transcript name | ||||
NCBI | Transcript variant 1 | Transcript variant 2 | Transcript variant 3 | − |
Ensembl | RAPGEF4-202 | RAPGEF4-203 | RAPGEF4-201 | |
ID | ||||
NCBI | ||||
Transcript | NM_001204165.1 | NM_019688.2 | NM_001204166.1 | − |
Protein | NP_001191094.1 | NP_062662.1 | NP_001191095.1 | − |
EBI | ||||
Transcript | ENSMUST00000090826.11 | ENSMUST00000102698.9 | ENSMUST00000028525.5 | − |
Protein | ENSMUSP00000088336.5 | ENSMUSP00000099759.3 | ENSMUSP00000028525.5 | − |
Exon number | 31 | 30 | 28 | |
Protein length (a.a) | 1011 | 993 | 867 | 696 |
Protein expression in tissuea | ||||
Brain | + | + | − | − |
Adrenal gl. | + | − | + | − |
Pancreas | + | − | + | − |
Kidney | − | − | + | − |
Liver | − | − | − | + |
Orthologous splicing isoform in human (NCBI ID) | Transcript variant 1 (NM_007023.4) | Transcript variant 8 (NM_001375866.1) | Transcript variant 2 (NM_001100397.2) |
aCitation from reference (5).